Compare Natera Inc. Common Stock (NTRA) vs XP Inc. Class A Common Stock (XP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs XP Inc. Class A Common Stock — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while XP Inc. Class A Common Stock trades at $30.06 (market cap $15.93B). The key difference: Natera Inc. Common Stock is far larger — about 3.6× XP Inc. Class A Common Stock's market cap, and XP Inc. Class A Common Stock pays a 0.64% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and XP Inc. Class A Common Stock for 5 Days on average.
| NTRA | XP | |
|---|---|---|
Market Cap | $57.03B | $15.93B |
Volume | 1,131,157 | 10,243,374 |
Sector | Health | Financials |
52-Week High | $425.64 | $32.60 |
52-Week Low | $179.42 | $14.94 |
Typical Hold Time | 0 Days | 5 Days |
Enterprise Value | $56.18B | $25.63B |
Dividend Yield | — | 0.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
XP Inc. trades at $31.38, down 3.74% today but remains near recent highs. The stock shows strong fundamental performance with 63.12% net income margin and 22.58% ROE, supported by consistent earnings beats in recent quarters. Technical indicators show mixed signals with bullish moving averages but overbought RSI readings. Analyst sentiment remains strongly positive with 80% buy ratings and price targets suggesting significant upside potential from current levels.
The outlook for XP remains favorable given its robust profitability metrics and growing revenue base, though investors should monitor competitive pressures and market volatility. The company's strong cash flow generation and institutional support provide stability, while technical overbought conditions suggest potential near-term consolidation before further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About XP Inc. Class A Common Stock
XP Inc. provides investment products and financial services in Brazil. Its platform includes brokerage, investment funds, fixed-income products, banking, insurance, and retirement solutions.
Read more on XP →
